Tedizolid phosphate oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations containing tedizolid phosphate.
Drugs List
Therapeutic Indications
Uses
Treatment of skin and skin structure infections
Dosage
Adults
200mg once daily for 6 days.
Elderly
200mg once daily for 6 days.
Additional Dosage Information
If a fast antibiotic effect is needed, parenteral tedizolid phosphate should be considered. See Monograph for parenteral tedizolid phosphate for further information.
Missed dose
If a dose is missed it should be given to the patient any time up to 8 hours prior to the next scheduled dose. If there are less than 8 hours before the next scheduled dose, wait to administer the next scheduled dose. Avoid double dosing.
Contraindications
Children under 18 years
Breastfeeding
Pregnancy
Precautions and Warnings
Severe immunosuppression
Neutropenia
Advise patient dizziness may affect ability to drive or operate machinery
Consult national/regional policy on the use of anti-infectives
Diabetic control may need adjustment
Perform blood counts on prolonged use of this treatment
Perform eye tests in any patient with vision change/ophthalmologic symptoms
Advise patient to report any blurred vision or any other eye symptoms
Consider C. difficile if diarrhoea occurs within 2 months of treatment
Discontinue therapy if marked diarrhoea occurs
Duration of treatment should not exceed 6 days
The manufacturer suggests alternative therapies should be considered when treating patients with neutropenia. The safety and efficacy of tedizolid phosphate in patients with neutrophil counts of less than 1000 cells per cubic millimetre have not been investigated. In an animal model of infection, the antibacterial activity of tedizolid phosphate was reduced in the absence of granulocytes. The clinical relevance of this finding is unknown.
Cases of thrombocytopenia have been observed when treatment lasted longer than the recommended duration. There may be an association with thrombocytopenia in patients with renal insufficiency.
Pregnancy and Lactation
Pregnancy
Tedizolid phosphate is contraindicated during pregnancy.
The manufacturer recommends tedizolid phosphate should be avoided during pregnancy.
At the time of writing, there are no data from the use of tedizolid phosphate in pregnant women. Studies in mice and rats showed developmental effects.
Lactation
Tedizolid phosphate is contraindicated during breastfeeding.
The manufacturer suggests a risk to the breastfeeding infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or tedizolid phosphate taking into consideration the benefit of breastfeeding for the child and the benefit of therapy for the patient. The Drugs and Lactation Database (LactMed) suggests that if required, tedizolid phosphate is not a reason to discontinue breastfeeding. However, the infant should be monitored for possible gastrointestinal tract effects. Alternate therapy may be prefered because of the lack of published data.
At the time of writing, it is unknown whether tedizolid phosphate is excreted in human milk. Tedizolid phosphate is excreted in the milk of rats.
Side Effects
Abdominal discomfort
Abdominal pain
Abscess
Acne
Alopecia
Antibiotic-associated colitis
Anxiety
Arthralgia
Back pain
Blurred vision
Bradycardia
Candidiasis (mouth or throat)
Chills
Constipation
Cough
Decreased glycaemic control in diabetes
Dehydration
Diarrhoea
Discomfort in limb
Dizziness
Dry mouth
Dysgeusia
Dyspepsia
Erythematous rash
Flatulence
Floaters
Flushing
Fungal infection
Gastroesophageal reflux disease
Haematochezia
Haemoglobin decrease
Headache
Hot flushes
Hyperhidrosis
Hyperkalaemia
Hypersensitivity reactions
Hypoaesthesia
Increase in serum transaminases
Insomnia
Irritability
Lymphadenopathy
Maculopapular rash
Muscle spasm
Nasal dryness
Nausea
Neck pain
Nightmares
Paraesthesia
Peripheral oedema
Pruritic rash
Pruritus
Pulmonary congestion
Pyrexia
Rash
Reduced neutrophil count
Reduced platelet count
Respiratory tract infection
Retching
Sleep disturbances
Somnolence
Thrombocytopenia
Tremor
Urine abnormality
Urticaria
Vomiting
Vulvovaginal infections
Vulvovaginal irritation
Weakness of the hands
White blood cell count decreased
Further Information
Last Full Review Date: October 2019
Reference Sources
Summary of Product Characteristics: Sivextro 200 mg film-coated tablets. Merck Sharp and Dohme. January 2021.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Tedizolid. Last revised: 04 September 2014.
Last accessed: 21 August 2017.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.